Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The company is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Follow-Up Questions
What is the price performance of RNLXY stock?
The current price of RNLXY is $0.217, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Renalytix PLC?
Renalytix PLC belongs to Health Care industry and the sector is Health Care
What is Renalytix PLC market cap?
Renalytix PLC's current market cap is $43.9M
Is Renalytix PLC a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Renalytix PLC, including 2 strong buy, 2 buy, 1 hold, 0 sell, and 2 strong sell
